IPOs Return, a Hedge Fund Unwinds, and the Fed's Liquidity Buffer Hits Zero

The IPO window is creaking open at the exact moment the market’s plumbing is being stress-tested from the other direction. July ended with the largest restaurant IPO on record, a 56% first-day biotech pop, and a three-deal biotech pipeline queued for the first week of August — all while Citadel absorbed a $16 billion forced liquidation from an AI-focused hedge fund and the Federal Reserve’s overnight reverse repo facility drained to a functional zero.

Whether the window stays open may depend less on issuer enthusiasm than on whether the leverage unwind stays contained. Assigning rough odds: I’d put the probability that the August biotech trio prices successfully at 70/30, but the probability that the broader market structure remains orderly through Q3 at closer to 55/45. The 45% case is the one worth thinking through.

Jersey Mike’s: A Billion-Dollar Debut With a Debt Hangover

Jersey Mike’s Subs (JMKE) priced 43.48 million Class A shares at $23 on July 29, raising approximately $1 billion and valuing the chain at roughly $7.3 billion — among the largest restaurant IPOs ever^[1]. The deal was led by Morgan Stanley, Bank of America, and Jefferies.

But the structure tells a more complicated story. Existing shareholders received roughly 68% of the proceeds, and the company directed nearly all of its net cash to pay down debt^[1]. In other words, this was partly a secondary offering dressed as an IPO — insiders cashing out while the company used the fresh capital to deleverage rather than fund expansion.

The market’s verdict was immediate. Shares opened at $21, below the $23 offer price, and closed the first session at $21.63, down 5.96%^[2]. By Friday, August 1, JMKE had recovered to $23^[2], but the initial break underscored investor skepticism about paying IPO premiums when most of the money exits via selling stockholders rather than funding growth.

Apnimed: The Biotech That Popped

The same week, Apnimed (APMD) demonstrated that investor appetite for clinical-stage biotech remains voracious when the narrative is compelling. The sleep-apnea-focused pharmaceutical company upsized its offering by 20% to 12 million shares and priced at $16 — the top of its range — raising $192 million^[2].

The stock closed its first session at $25, a 56.3% gain that pushed the company’s market value near $1 billion^[2]. The first-day move was driven by optimism around the company’s lead candidate and a forthcoming FDA decision that could expand the addressable market for oral sleep-apnea therapeutics. When a biotech prices at the top, upsizes, and still pops 56%, the demand curve is steeper than the sell-side models assumed.

The Biotech Pipeline: $500 Million-Plus Coming in August

The IPO calendar for the first full week of August is dominated by a trio of clinical-stage biotechs collectively seeking more than $500 million^[3]:

Attovia, a Phase 1 biotech developing biotherapeutics for immune-mediated diseases, set terms on July 29 with a syndicate led by Morgan Stanley and Leerink Partners^[3]. Braveheart Bio, a Phase 3-ready cardiovascular company, followed on July 30 with Goldman Sachs and Jefferies leading the book; Fidelity indicated on $75 million of the deal^[3]. Vogenx, targeting metabolic disease, rounds out the trio with a smaller $75 million raise through JonesTrading^[4].

Additional smaller deals are queued behind them: Web3Labs Global (MDAT), BW Industrial Holdings (BWGC), MetaOptics (MOT, an uplisting), and Riku Dining Group (RIKU) are all targeting the week of August 10^[4].

The Citadel Rescue: What a Leverage Unwind Looks Like

While new issuers lined up to sell stock, the market’s existing infrastructure absorbed a very different kind of transaction. On July 30, Situational Awareness — an AI-focused hedge fund run by former OpenAI researcher Leopold Aschenbrenner — sold the bulk of its public equities portfolio to Ken Griffin’s Citadel after a 67% drawdown in July^[5].

The fund, which had managed approximately $20 billion and used roughly 4x leverage to amplify concentrated bets on AI infrastructure stocks — including Broadcom, Intel, and CoreWeave — was down 67% for the month after returning 439% in the first half of the year^[5]. The portfolio sold was reported at roughly $16 billion, acquired by Citadel at more than a 10% discount to prior value^[6].

The deal was facilitated by a consortium of prime brokers — Goldman Sachs, JPMorgan Chase, Bank of America, and Citigroup — and involved Citadel taking the portion of the portfolio financed by broker leverage^[5]. Situational Awareness retains a book of roughly $10 billion, including private investments such as its stake in Anthropic, which was not sold^[5].

This episode is a market-structure story as much as a hedge-fund story. Goldman’s prime brokerage note flagged that Asia-focused fundamental long-short funds were down 18.6% on average through July 28 — the biggest monthly drawdown on record for the category^[5]. Morgan Stanley’s prime desk reported that hedge funds were unwinding AI positions, covering shorts and selling longs in roughly equal measure^[5]. When leveraged positions are forced into a bid simultaneously, the plumbing matters — and the plumbing is losing its buffer.

The historical analogy that comes to mind is not 2008 but the September 2019 repo spike, when a specific set of institutional constraints produced a sudden, localized funding seizure beneath a seemingly calm surface. The Situational Awareness unwind was absorbed — Citadel’s willingness to step in is the reason it was absorbed — but the next forced seller may not find a counterparty of that size waiting.

The Fed’s Reverse Repo: From Shock Absorber to Zero

The Federal Reserve’s Overnight Reverse Repurchase Agreement (ON RRP) facility — the mechanism that allowed money market funds to park excess cash at the Fed — has collapsed to a functional zero. As of July 30, the facility held approximately $1.076 billion, down from a peak above $2 trillion in 2023^[7].

For most of the post-pandemic period, the ON RRP served as a liquidity shock absorber: as quantitative tightening drained reserves from the banking system, the facility’s balances shrank first, shielding bank reserves from the impact. With that buffer now effectively exhausted, any further reserve drain from QT flows directly into the banking system^[7].

This is not an immediate crisis trigger. But it removes a layer of insulation at exactly the moment when forced deleveraging is visible in the system. The question is whether the current plumbing, without the RRP buffer, is more or less resilient than it was in September 2019 — and whether the Fed’s next move on QT pace comes proactively or reactively.

Buybacks Continue, But the Mix Is Shifting

While the IPO calendar revives and hedge funds deleverage, corporate buybacks remain a steady source of demand. Several major programs were announced or progressed in the final week of July:

• Shell (SHEL): Announced a $3 billion buyback program on July 30, plus $1.23 billion remaining from a prior authorization^[8].
• Vale (VALE): Launched a 100 million-share repurchase program^[8].
• ING (ING): Ongoing under its €1 billion program, repurchasing 865,193 shares the week of July 20–24 at an average price of €28.83^[8].
• BASF (BAS): Announced a new buyback program beginning August 2026^[8].
• News Corp (NWS): Continued activity under a $1 billion authorization^[8].
• Prosus (PRX): Ongoing open-ended repurchase program^[8].

The mix is notable: energy, mining, European financials, and media — not the AI-adjacent names that dominated hedge fund positioning. The buyback engine is running, but it is not concentrated in the same sectors where leverage is being unwound. That divergence is, on balance, a stabilizing force: demand for shares is coming from balance-sheet-strong corporates in different industries than the ones experiencing forced selling.

What to Watch Next

1. Attovia, Braveheart, and Vogenx pricing (Aug 5–6): Do all three price within range, or does one get pulled? The read-through from these deals will shape the biotech IPO calendar for the rest of Q3. If all three clear, the window is genuinely open. If one is withdrawn or prices below range, the signal is that demand is selective.

2. Situational Awareness’s remaining portfolio: The fund retains roughly $10 billion, including its Anthropic stake. Any further liquidation — or a secondary sale of private positions — would be a signal about AI-adjacent valuations and could reignite the de-grossing cycle.

3. Jersey Mike’s first full week of trading: Does it hold above $23, or does the debt-and-selling-stockholder structure keep a lid on the stock? Restaurant IPOs are rare; the performance read-through matters for any consumer-franchise issuer waiting in the wings.

4. Fed balance sheet and reserves: With the ON RRP at zero, the next H.4.1 release will show whether bank reserves are declining. If the Fed signals a slowdown or pause in QT at the September FOMC, it would be directly related to the loss of the RRP buffer.

5. Hedge fund de-grossing breadth: Goldman and Morgan Stanley’s prime notes suggest the AI unwind is not limited to one fund. Watch for whether the de-leveraging spreads to other crowded trades or stabilizes as positions are transferred to stronger hands. The weekly dark-pool and prime brokerage data will tell you whether this is a one-fund event or a cycle.

FN2 Research provides market commentary and education, not personalized investment advice.